Krsnaa Diagnostics Peer Comparison

NSE: KRSNAA | BSE: 543328

₹564.05

₹6.35 (1.14%)

As on 28-Aug-2026IST

Market cap

₹1,829 Cr

Revenue (TTM)

₹815 Cr

P/E Ratio

18.8

P/B Ratio

1.8

Div. Yield

0.4 %

Edit

	Krsnaa Diagnostics	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Market cap (₹ Cr)	1,829	39,538	32,407	32,332	14,953
Revenue (₹ Cr)	815	4,683	2,891	4,213	857
Net Profit (₹ Cr)	97.53	552.34	546.30	190.80	187.49
Net Margin (%)	11.31	11.55	18.23	4.49	21.32
RoE (%)	10.24	14.93	23.03	9.45	20.58
Price to Earnings	18.76	71.09	59.80	158.26	79.76
Price-To-Book	1.83	9.62	12.40	8.54	14.85

Income Statement (₹ Cr)

	Krsnaa Diagnostics	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Operating Revenue	815.33	4,683.37	2,890.80	4,212.50	857.13
Total Income	862.01	4,783.78	2,995.90	4,248.00	879.41
Total Expenditure	596.87	3,704.62	2,053.10	3,379.70	495.19
EBITDA	218.46	978.75	837.70	832.80	361.94
Depreciation	96.78	246.41	171.60	330.60	96.06
EBIT	121.67	732.34	666.10	502.20	265.89
Interest	42.90	92.01	24.40	253.30	36.75
Other Income	46.68	100.41	105.10	35.50	22.28
Exceptional Items	0.00	-20.61	-30.10	-11.20	0.00
Profit before Tax	125.45	720.14	716.70	273.20	251.42
Provision for Tax	27.92	167.80	170.40	82.40	63.93
Profit after Tax	97.53	552.34	546.30	190.80	187.49

	Krsnaa Diagnostics	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Shareholder's Funds	980.39	3,961.57	2,508.20	2,247.40	957.15
Minority Interest	0.00	3.84	-4.40	9.90	0.00
Non-Current Liabilities	568.13	1,293.60	154.00	3,961.30	426.03
Current Liabilities	275.20	627.13	450.70	1,238.90	123.87
Total Liabilities	--	4,766.23	2,713.41	5,689.20	1,273.62

	Krsnaa Diagnostics	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Non-Current Assets	927.01	3,128.95	1,176.30	5,416.90	737.24
Current Assets	738.34	1,674.92	1,566.60	937.40	321.90
Total Assets	--	4,766.23	2,713.41	5,689.20	1,273.62
Total Debt*	--	327.88	0.00	1,910.90	0.00
Net Current Assets	463.14	1,047.79	1,115.90	-301.50	198.03
Contingent Liabilities	--	88.77	10.59	83.80	0.13

	Krsnaa Diagnostics	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Cash From Operating Activities	--	623.76	568.89	581.80	224.47
Cash Flow from Investing Activities	--	-720.94	-303.16	-1,116.20	-181.88
Cash from Financing Activities	--	-97.23	-334.03	543.10	-52.05
Net Cash Inflow / Outflow	--	-194.41	-68.31	8.70	-9.45

	Krsnaa Diagnostics	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
ROCE (%)	--	20.50	31.53	19.02	30.20
ROE (%)	10.24	14.93	23.03	9.45	20.58
ROA (%)	6.28	10.35	18.64	2.83	13.49
EBIT Margin (%)	14.92	15.64	23.04	11.92	31.02
Net Margin (%)	11.31	11.55	18.23	4.49	21.32
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Krsnaa Diagnostics	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Revenue Growth (%)	10.19	21.27	14.29	30.90	20.18
EBIT Growth (%)	10.24	0.94	15.64	-16.88	26.22
Net Profit Growth (%)	21.61	3.43	5.38	-52.81	24.27
EPS Growth (%)	21.09	2.70	-30.51	-42.60	23.44
Book Value Growth (%)	--	16.71	17.68	16.93	19.36

	Krsnaa Diagnostics	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Price / Earnings	18.76	69.04	45.29	145.70	79.61
Price / Book Value	1.83	9.62	12.40	8.54	14.85
Dividend Yield (%)	0.35	0.03	1.06	0.00	0.14
EV/EBITDA	8.99	39.89	37.09	42.61	40.54
Market Cap (₹ Cr)	--	32,181.74	20,714.85	25,571.93	10,333.01

	Krsnaa Diagnostics	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Debt to Equity	0.45	0.15	0.00	1.19	0.00
Short term debt to equity ratio	--	--	--	0.06	--
Current Ratio	2.68	2.67	3.48	0.76	2.60
Quick Ratio	2.59	2.54	3.38	0.68	2.56
Interest Coverage	3.92	8.83	30.37	2.08	7.84

	Krsnaa Diagnostics	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Debtors to sales (%)	36.24	8.78	3.83	13.16	2.43
Asset Turnover	0.53	0.88	0.99	0.62	0.62
Receivable days	--	25.07	12.27	41.48	8.30
Inventory Days	--	6.62	5.45	6.82	2.71
Payable days	--	79.17	134.04	135.60	142.28
Cash Conversion Cycle	--	-47.48	-116.32	-87.31	-131.27

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.